

February 23, 2016

Whom It May Concern

Company: KYORIN Holdings, Inc.
Representative: Minoru Hogawa
Representative Director, President
(Security Code: 4569, TSE 1st Sec.)
Contact: Shuji Miyaki
Director, Corporate Communication
President Office
Telephone: (0)3-3525-4707

Announcement Regarding Montelukast tablets 10mg 「KM」 , Montelukast tablets 5mg 「KM」

TOKYO, Japan (February 23, 2016) —KYORIN Rimedio Co., Ltd. (Head office: Kanazawa City, Ishikawa, President: Michiro Oonota), a wholly owned subsidiary of KYORIN Holdings, Inc., announced today that is currently applying for listing on the NHI (National Health Insurance) Price List for a treatment for bronchial asthma and allergic rhinitis drug “Montelukast tablets 10mg , 5mg 「KM」 ” (Active ingredient : Montelukast Sodium), which obtained a manufacturing and marketing license on 15 February, 2016

This drug is an authorized generic drug for KIPRES and SINGULAIR, a treatment for bronchial asthma and allergic rhinitis drugs which are being sold by KYORIN Holdings’ subsidiary KYORIN Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President : Mitsutomo Miyashita) and MSD K.K. (Headquarters: Chiyoda-ku, Tokyo, President: Tony Alvarez).

KYORIN Rimedio Co., Ltd. has entered into a basic agreement licensing the patent rights, etc. with an affiliated company of MSD K.K., and plans to sell this drug once it is listed on the drug price list (Manufacturer and seller: KYORIN Rimedio Co., Ltd. , Seller: KYORIN Pharmaceutical Co., Ltd.).

The provisions of the agreement regarding this drug and the details of sales activities going forward have not been disclosed.

Kyorin Group, based on its corporate philosophy of “Contributing to better health”, will continue striving to provide pharmaceuticals that meet the wide-ranging needs of patients and medical professionals.